Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

SI-BONE Yönetim

Yönetim kriter kontrolleri 3/4

SI-BONE's CEO'su Laura Francis, Apr2021 tarihinde atandı, in görev süresi 3.5 yıldır. in toplam yıllık tazminatı $ 3.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.8% maaş ve 83.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.83% ine doğrudan sahiptir ve bu hisseler $ 4.81M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 13.8 yıldır.

Anahtar bilgiler

Laura Francis

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi	16.8%
CEO görev süresi	3.5yrs
CEO sahipliği	0.8%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	13.8yrs

Son yönetim güncellemeleri

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Sep 25

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

CEO Tazminat Analizi

Laura Francis'un ücretlendirmesi SI-BONE'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$41m
Mar 31 2024	n/a	n/a	-US$43m
Dec 31 2023	US$4m	US$622k	-US$43m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$5m	US$604k	-US$61m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$3m	US$527k	-US$57m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$2m	US$386k	-US$44m
Sep 30 2020	n/a	n/a	-US$44m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$2m	US$375k	-US$38m
Sep 30 2019	n/a	n/a	-US$35m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$734k	US$319k	-US$17m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$518k	US$302k	-US$23m

Tazminat ve Piyasa: Laura 'nin toplam tazminatı ($USD 3.71M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Laura 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Laura Francis (57 yo)

3.5yrs

Görev süresi

US$3,713,871

Tazminat

Ms. Laura A. Francis, MBA, serves as Chief Executive Officer and Director at SI-BONE, Inc. since April 18, 2021. She was Chief Financial Officer of SI-Bone Inc. since May 26, 2015 until April 18, 2021 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laura Francis	CEO & Director	3.5yrs	US$3.71m	0.83% $ 4.7m
Anshul Maheshwari	Chief Financial Officer	3.5yrs	US$1.86m	0.15% $ 874.0k
Anthony Recupero	President of Commercial Operations	8.3yrs	US$2.06m	0.22% $ 1.3m
Jeff Bertolini	Senior Vice President of Operations & Information Technology	2.3yrs	Veri yok	Veri yok
Scott Yerby	Senior VP of Engineering & CTO	no data	Veri yok	Veri yok
Saqib Iqbal	Director of FP&A and Investor Relations	no data	Veri yok	Veri yok
Michael Pisetsky	Chief Business & Legal Affairs Officer	8.2yrs	Veri yok	0.13% $ 731.1k
Aimee Einstein	Vice President of People & Culture	2.8yrs	Veri yok	Veri yok
Daniel Cher	Senior Vice President of Clinical & Regulatory Affairs	3.3yrs	Veri yok	Veri yok
W. Reckling	Chief Medical Officer & VP of Medical Affairs	no data	Veri yok	Veri yok
Nikolas Kerr	Senior Vice President of Product	3.5yrs	Veri yok	Veri yok
Troy Wahlenmaier	Senior Vice President of US Sales	less than a year	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: SIBN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Laura Francis	CEO & Director	3.5yrs	US$3.71m	0.83% $ 4.7m
Timothy Davis	Lead Independent Director	16.5yrs	US$211.30k	0.093% $ 525.8k
Gregory Hinckley	Independent Director	13.8yrs	US$191.30k	0.38% $ 2.2m
Jeryl Hilleman	Independent Director	4.8yrs	US$206.30k	0.025% $ 142.8k
John Freund	Independent Director	11.8yrs	US$188.30k	0.31% $ 1.8m
Ralph Rashbaum	Member of Medical Advisory Board	14.8yrs	Veri yok	Veri yok
Steven Garfin	Member of Medical Advisory Board	14.8yrs	Veri yok	Veri yok
Frank Phillips	Member of Medical Advisory Board	14.8yrs	Veri yok	Veri yok
Jeffrey Dunn	Executive Chairman	16.5yrs	US$551.18k	0.26% $ 1.4m
A. Shamie	Member of Medical Advisory Board	13.8yrs	Veri yok	Veri yok
Mika Nishimura	Independent Director	3.6yrs	US$188.30k	0.046% $ 263.6k
Jonathan Hyde	Member of Surgeon Advisory Board	no data	Veri yok	Veri yok

13.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SIBN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 13.8 yıldır).

SI-BONE Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

CEO & Director recently sold US$809k worth of stock

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Executive Chairman exercised options and sold US$337k worth of stock

Recent updates

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Revises Financial Guidance for 2024

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

New minor risk - Profitability

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2026

CEO & Director recently sold US$809k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 7.3% to US$28.38

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Executive Chairman exercised options and sold US$337k worth of stock

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

Executive Chairman notifies of intention to sell stock

CEO & Director recently sold US$189k worth of stock

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$616k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold US$224k worth of stock

President of Commercial Operations notifies of intention to sell stock

Executive Chairman exercised options and sold US$5.1m worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Key Executive notifies of intention to sell stock

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 16% to US$24.50

President of Commercial Operations notifies of intention to sell stock

CEO & Director recently sold US$226k worth of stock

Executive Chairman notifies of intention to sell stock

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Price target decreased to US$22.38

Executive Chairman recently sold US$105k worth of stock

CEO & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Executive Chairman recently sold US$138k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SI-BONE, Inc. to Report Q2, 2022 Results on Aug 08, 2022

SI-BONE, Inc. Announces FDA Clearance for Expanded Indication of the iFuse-TORQ® Implant System

SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite